Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.
Identifieur interne : 000753 ( PubMed/Checkpoint ); précédent : 000752; suivant : 000754Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.
Auteurs : Francesca Antonelli [Canada] ; Ji Hyun Ko ; Janis Miyasaki ; Anthony E. Lang ; Sylvain Houle ; Franco Valzania ; Nicola J. Ray ; Antonio P. StrafellaSource :
- Human brain mapping [ 1097-0193 ] ; 2014.
English descriptors
- KwdEn :
- Benzothiazoles (pharmacology), Brain (diagnostic imaging), Brain (drug effects), Brain (physiopathology), Brain Mapping, Choice Behavior (drug effects), Choice Behavior (physiology), Dopamine Agonists (pharmacology), Female, Humans, Impulsive Behavior (drug effects), Impulsive Behavior (physiology), Male, Middle Aged, Neuropsychological Tests, Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Positron-Emission Tomography, Reward, Signal Processing, Computer-Assisted, Task Performance and Analysis.
- MESH :
- chemical , pharmacology : Benzothiazoles, Dopamine Agonists.
- diagnostic imaging : Brain, Parkinson Disease.
- drug effects : Brain, Choice Behavior, Impulsive Behavior.
- drug therapy : Parkinson Disease.
- physiology : Choice Behavior, Impulsive Behavior.
- physiopathology : Brain, Parkinson Disease.
- Brain Mapping, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Positron-Emission Tomography, Reward, Signal Processing, Computer-Assisted, Task Performance and Analysis.
Abstract
The control of impulse behavior is a multidimensional concept subdivided into separate subcomponents, which are thought to represent different underlying mechanisms due to either disinhibitory processes or poor decision-making. In patients with Parkinson's disease (PD), dopamine-agonist (DA) therapy has been associated with increased impulsive behavior. However, the relationship among these different components in the disease and the role of DA is not well understood. In this imaging study, we investigated in PD patients the effects of DA medication on patterns of brain activation during tasks testing impulsive choices and actions. Following overnight withdrawal of antiparkinsonian medication, PD patients were studied with a H2 ((15)) O PET before and after administration of DA (1 mg of pramipexole), while they were performing the delay discounting task (DDT) and the GoNoGo Task (GNG). We observed that pramipexole augmented impulsivity during DDT, depending on reward magnitude and activated the medial prefrontal cortex and posterior cingulate cortex and deactivated ventral striatum. In contrast, the effect of pramipexole during the GNG task was not significant on behavioral performance and involved different areas (i.e., lateral prefrontal cortex). A voxel-based correlation analysis revealed a significant negative correlation between the discounting value (k) and the activation of medial prefrontal cortex and posterior cingulate suggesting that more impulsive patients had less activation in those cortical areas. Here we report how these different subcomponents of inhibition/impulsivity are differentially sensitive to DA treatment with pramipexole influencing mainly the neural network underlying impulsive choices but not impulsive action.
DOI: 10.1002/hbm.22344
PubMed: 24038587
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24038587Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.</title><author><name sortKey="Antonelli, Francesca" sort="Antonelli, Francesca" uniqKey="Antonelli F" first="Francesca" last="Antonelli">Francesca Antonelli</name><affiliation wicri:level="4"><nlm:affiliation>Morton and Gloria Shulman Movement Disorder Unit, E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit, E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name></author><author><name sortKey="Valzania, Franco" sort="Valzania, Franco" uniqKey="Valzania F" first="Franco" last="Valzania">Franco Valzania</name></author><author><name sortKey="Ray, Nicola J" sort="Ray, Nicola J" uniqKey="Ray N" first="Nicola J" last="Ray">Nicola J. Ray</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24038587</idno><idno type="pmid">24038587</idno><idno type="doi">10.1002/hbm.22344</idno><idno type="wicri:Area/PubMed/Corpus">000739</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000739</idno><idno type="wicri:Area/PubMed/Curation">000739</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000739</idno><idno type="wicri:Area/PubMed/Checkpoint">000739</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000739</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.</title><author><name sortKey="Antonelli, Francesca" sort="Antonelli, Francesca" uniqKey="Antonelli F" first="Francesca" last="Antonelli">Francesca Antonelli</name><affiliation wicri:level="4"><nlm:affiliation>Morton and Gloria Shulman Movement Disorder Unit, E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit, E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name></author><author><name sortKey="Valzania, Franco" sort="Valzania, Franco" uniqKey="Valzania F" first="Franco" last="Valzania">Franco Valzania</name></author><author><name sortKey="Ray, Nicola J" sort="Ray, Nicola J" uniqKey="Ray N" first="Nicola J" last="Ray">Nicola J. Ray</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></analytic><series><title level="j">Human brain mapping</title><idno type="eISSN">1097-0193</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzothiazoles (pharmacology)</term><term>Brain (diagnostic imaging)</term><term>Brain (drug effects)</term><term>Brain (physiopathology)</term><term>Brain Mapping</term><term>Choice Behavior (drug effects)</term><term>Choice Behavior (physiology)</term><term>Dopamine Agonists (pharmacology)</term><term>Female</term><term>Humans</term><term>Impulsive Behavior (drug effects)</term><term>Impulsive Behavior (physiology)</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Positron-Emission Tomography</term><term>Reward</term><term>Signal Processing, Computer-Assisted</term><term>Task Performance and Analysis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzothiazoles</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Choice Behavior</term><term>Impulsive Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Choice Behavior</term><term>Impulsive Behavior</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Brain Mapping</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Positron-Emission Tomography</term><term>Reward</term><term>Signal Processing, Computer-Assisted</term><term>Task Performance and Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The control of impulse behavior is a multidimensional concept subdivided into separate subcomponents, which are thought to represent different underlying mechanisms due to either disinhibitory processes or poor decision-making. In patients with Parkinson's disease (PD), dopamine-agonist (DA) therapy has been associated with increased impulsive behavior. However, the relationship among these different components in the disease and the role of DA is not well understood. In this imaging study, we investigated in PD patients the effects of DA medication on patterns of brain activation during tasks testing impulsive choices and actions. Following overnight withdrawal of antiparkinsonian medication, PD patients were studied with a H2 ((15)) O PET before and after administration of DA (1 mg of pramipexole), while they were performing the delay discounting task (DDT) and the GoNoGo Task (GNG). We observed that pramipexole augmented impulsivity during DDT, depending on reward magnitude and activated the medial prefrontal cortex and posterior cingulate cortex and deactivated ventral striatum. In contrast, the effect of pramipexole during the GNG task was not significant on behavioral performance and involved different areas (i.e., lateral prefrontal cortex). A voxel-based correlation analysis revealed a significant negative correlation between the discounting value (k) and the activation of medial prefrontal cortex and posterior cingulate suggesting that more impulsive patients had less activation in those cortical areas. Here we report how these different subcomponents of inhibition/impulsivity are differentially sensitive to DA treatment with pramipexole influencing mainly the neural network underlying impulsive choices but not impulsive action.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24038587</PMID><DateCreated><Year>2014</Year><Month>04</Month><Day>22</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0193</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Human brain mapping</Title><ISOAbbreviation>Hum Brain Mapp</ISOAbbreviation></Journal><ArticleTitle>Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.</ArticleTitle><Pagination><MedlinePgn>2499-506</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hbm.22344</ELocationID><Abstract><AbstractText>The control of impulse behavior is a multidimensional concept subdivided into separate subcomponents, which are thought to represent different underlying mechanisms due to either disinhibitory processes or poor decision-making. In patients with Parkinson's disease (PD), dopamine-agonist (DA) therapy has been associated with increased impulsive behavior. However, the relationship among these different components in the disease and the role of DA is not well understood. In this imaging study, we investigated in PD patients the effects of DA medication on patterns of brain activation during tasks testing impulsive choices and actions. Following overnight withdrawal of antiparkinsonian medication, PD patients were studied with a H2 ((15)) O PET before and after administration of DA (1 mg of pramipexole), while they were performing the delay discounting task (DDT) and the GoNoGo Task (GNG). We observed that pramipexole augmented impulsivity during DDT, depending on reward magnitude and activated the medial prefrontal cortex and posterior cingulate cortex and deactivated ventral striatum. In contrast, the effect of pramipexole during the GNG task was not significant on behavioral performance and involved different areas (i.e., lateral prefrontal cortex). A voxel-based correlation analysis revealed a significant negative correlation between the discounting value (k) and the activation of medial prefrontal cortex and posterior cingulate suggesting that more impulsive patients had less activation in those cortical areas. Here we report how these different subcomponents of inhibition/impulsivity are differentially sensitive to DA treatment with pramipexole influencing mainly the neural network underlying impulsive choices but not impulsive action.</AbstractText><CopyrightInformation>Copyright © 2013 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorder Unit, E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ji Hyun</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Valzania</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>Antonio P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>110962-1</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP 110962</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Brain Mapp</MedlineTA><NlmUniqueID>9419065</NlmUniqueID><ISSNLinking>1065-9471</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="C061333">pramipexole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2011 Nov 15;310(1-2):202-7</RefSource><PMID Version="1">21683964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscientist. 2007 Jun;13(3):214-28</RefSource><PMID Version="1">17519365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 1996;4(1):58-73</RefSource><PMID Version="1">20408186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Cogn Sci. 2008 Jan;12(1):7-12</RefSource><PMID Version="1">18042423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Psychol Learn Mem Cogn. 2003 Jan;29(1):66-79</RefSource><PMID Version="1">12549584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Psychiatry. 2007 May;20(3):255-61</RefSource><PMID Version="1">17415079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 2012 Apr 30;202(1):20-9</RefSource><PMID Version="1">22633679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 1993 Dec;18(3):249-52</RefSource><PMID Version="1">8127474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 2007 May;28(5):383-93</RefSource><PMID Version="1">16944492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1376-85</RefSource><PMID Version="1">19346328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2004 Oct 15;306(5695):503-7</RefSource><PMID Version="1">15486304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2003 Jul;19(3):1233-9</RefSource><PMID Version="1">12880848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 1996;4(2):140-51</RefSource><PMID Version="1">20408193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2005 Apr;53(4):695-9</RefSource><PMID Version="1">15817019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2012 Dec;48(3):519-25</RefSource><PMID Version="1">22766031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2002 Nov;27(5):813-25</RefSource><PMID Version="1">12431855</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2007 Nov 23;318(5854):1309-12</RefSource><PMID Version="1">17962524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cereb Cortex. 2000 Mar;10(3):295-307</RefSource><PMID Version="1">10731224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Brain Res Rev. 2001 Oct;36(2-3):139-49</RefSource><PMID Version="1">11690610</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Nov 9;75(19):1711-6</RefSource><PMID Version="1">20926784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Jul;18(7):738-50</RefSource><PMID Version="1">12815652</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1989 Aug 21;495(1):100-7</RefSource><PMID Version="1">2776028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1999 May;122 ( Pt 5):981-91</RefSource><PMID Version="1">10355680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2001 Jun 29;292(5526):2499-501</RefSource><PMID Version="1">11375482</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Stimul. 2010 Jul;3(3):170-6</RefSource><PMID Version="1">20633446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Dec;66(6):817-24</RefSource><PMID Version="1">20035509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 1999 Oct;146(4):455-64</RefSource><PMID Version="1">10550496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2002 Jan;15(1):273-89</RefSource><PMID Version="1">11771995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 2007 Jun;179(4):643-53</RefSource><PMID Version="1">17216152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Anal Behav. 1999 Mar;71(2):121-43</RefSource><PMID Version="1">10220927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Psychol Gen. 1999 Mar;128(1):78-87</RefSource><PMID Version="1">10100392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Dec 4;40(5):1031-40</RefSource><PMID Version="1">14659101</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Neurol. 2011 Aug;24(4):324-30</RefSource><PMID Version="1">21725242</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012815" MajorTopicYN="N">Signal Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">CAMS4599</OtherID><OtherID Source="NLM">PMC4452224</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">dopamine agonists</Keyword><Keyword MajorTopicYN="N">impulsivity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24038587</ArticleId><ArticleId IdType="doi">10.1002/hbm.22344</ArticleId><ArticleId IdType="pmc">PMC4452224</ArticleId><ArticleId IdType="mid">CAMS4599</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><name sortKey="Ray, Nicola J" sort="Ray, Nicola J" uniqKey="Ray N" first="Nicola J" last="Ray">Nicola J. Ray</name><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name><name sortKey="Valzania, Franco" sort="Valzania, Franco" uniqKey="Valzania F" first="Franco" last="Valzania">Franco Valzania</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Antonelli, Francesca" sort="Antonelli, Francesca" uniqKey="Antonelli F" first="Francesca" last="Antonelli">Francesca Antonelli</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000753 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000753 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24038587
|texte= Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24038587" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |